GHRH 类似物 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-01-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
Measured responses usually involve growth hormone and insulin-like growth factor 1, known as IGF-1. Growth hormone rises in bursts and is difficult to sample reliably, while IGF-1 shifts more slowly and can be assessed from a single blood draw. Studies therefore treat IGF-1 as the more practical pharmacodynamic marker. Both are indirect, showing that the receptor was engaged rather than that the peptide reached a particular concentration. Direct exposure measurement requires an assay aimed at the molecule itself.
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | N-terminal trans-3-hexenoyl group |
| Approximate mass | About 5.1 kDa | Derived from the peptide sequence |
| Primary target | Pituitary GHRH receptor | Somatotroph cells of the anterior pituitary |
| Downstream marker | IGF-1 | Measured indirectly in circulation |
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。
Identity and purity are judged through a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact peptide from truncated, oxidized, and deamidated variants, and the resulting peak-area percentages yield a purity figure. Electrospray ionization mass spectrometry confirms the expected molecular mass and can expose unanticipated modifications. Amino acid analysis and peptide mapping support sequence fidelity, while water content, pH, sterility, and bacterial endotoxin testing describe the physical and microbiological attributes of a finished lot.
Regulatory position depends on jurisdiction and on the form in which the material is sold. A branded product holds approval in the United States for a defined indication, and prescribing is confined to that label. Material marketed for laboratory research is not evaluated for human use and carries no such clearance. Independent verification therefore rests on certificates of analysis, third-party testing, and documented chain of custody. The substance also appears on the World Anti-Doping Agency prohibited list within the category covering growth hormone-releasing factors.
Lyophilized material is typically held under refrigeration between two and eight degrees Celsius, shielded from light and ambient moisture. Peptides of this size adsorb to glass and plastic, so working procedures often call for low-binding containers and as few transfers as possible. Absorbed water during weighing shifts the apparent mass of a sample, and controlling room humidity reduces that source of error. Once dissolved, solutions are kept cold and used within the interval printed on the accompanying label or certificate. Degradation accelerates markedly in dilute aqueous form.
Lee, a longtime fan of baseball, donated 200 baseballs signed by famous Negro league players including Willie Mays, Hank Aaron, and Josh Gibson, to the Negro Leagues Baseball Museum in Kansas City, Missouri in June 2008. In late 2009, Lee and Lifeson launched an auction for their initiative "Grapes Under Pressure", in support of "Grapes for Humanity", a charity. The auction consisted of items from the band such as autographed guitars, cymbals and basses. There were autographs by band members from Depeche Mode, Tool, the Fray, Judas Priest, Pearl Jam and other bands in addition to a rare Epiphone guitar with signatures from Ricky, Julian, and Bubbles from Trailer Park Boys. The band is featured on the album Songs for Tibet, appearing with other celebrities as an initiative to support Tibet and Dalai Lama Tenzin Gyatso. The album, made downloadable on August 5, 2008, via iTunes, was released commercially on August 12, 2008. Rush have also been big supporters of Little Kids Rock, a nonprofit which works to restore and revitalize music education programmes in disadvantaged US public schools. Musician's Friend, Sabian, and Rush teamed to help Little Kids Rock provide percussion to public schools nationwide. They donated $500 of the proceeds from each Neil Peart Paragon Cymbal Pack sold, each of which came with a free splash cymbal personally autographed by Peart. The marketing initiative raised over $50,000 for Little Kids Rock.
=== Part IV: Transitional programme === Part IV provides a general outline of the remaining actions to be taken during the transitional period. It assigns the Council of Representatives with the responsibility to oversee the creation of a draft constitution that would eventually be presented to the Constituent Assembly before being formally adopted. Article twelve briefly mandates that elections for a National Assembly, must be held within the following two years; the Transitional Government was expected to hand over power to the parties who make up a majority of the Assembly.
Selenium, especially in the II oxidation state, forms a variety of organic derivatives. They are structurally analogous to the corresponding organosulfur compounds. Especially common are selenides (R2Se, analogues of thioethers), diselenides (R2Se2, analogues of disulfides), and selenols (RSeH, analogues of thiols). Representatives of selenides, diselenides, and selenols include respectively selenomethionine, diphenyldiselenide, and benzeneselenol. The sulfoxide in sulfur chemistry is represented in selenium chemistry by the selenoxides (formula RSe(O)R), which are intermediates in organic synthesis, as illustrated by the selenoxide elimination reaction. Consistent with trends indicated by the double bond rule, selenoketones, R(C=Se)R, and selenaldehydes, R(C=Se)H, are rarely observed.
A polyproline helix is a type of protein secondary structure which occurs in proteins comprising repeating proline residues. A left-handed polyproline II helix (PPII, poly-Pro II, κ-helix) is formed when sequential residues all adopt (φ,ψ) backbone dihedral angles of roughly (-75°, 150°) and have trans isomers of their peptide bonds. This PPII conformation is also common in proteins and polypeptides with other amino acids apart from proline. Similarly, a more compact right-handed polyproline I helix (PPI, poly-Pro I) is formed when sequential residues all adopt (φ,ψ) backbone dihedral angles of roughly (-75°, 160°) and have cis isomers of their peptide bonds. Of the twenty common naturally occurring amino acids, only proline is likely to adopt the cis isomer of the peptide bond, specifically the X-Pro peptide bond; steric and electronic factors heavily favor the trans isomer in most other peptide bonds. However, peptide bonds that replace proline with another N-substituted amino acid (such as sarcosine) are also likely to adopt the cis isomer.
Sources: en.wikipedia.org
=== Warfare and weapons === At RAF Bomber Command, Dyson and colleagues proposed removing two gun turrets from Avro Lancaster bombers, to cut the catastrophic losses due to German fighters in the Battle of Berlin. A Lancaster without turrets could fly 50 mph (80 km/h) faster and be much more manoeuvrable.
===== MeSH D08.811.913.400 – glycosyltransferases (EC 2.4) ===== MeSH D08.811.913.400.100 – n-acetylhexosaminyltransferases MeSH D08.811.913.400.100.200 – n-acetylgalactosaminyltransferases MeSH D08.811.913.400.100.200.300 – fucosyl galactose alpha-n-acetylgalactosaminyltransferase MeSH D08.811.913.400.100.250 – n-acetylglucosaminyltransferases MeSH D08.811.913.400.450 – hexosyltransferases MeSH D08.811.913.400.450.300 – fucosyltransferases MeSH D08.811.913.400.450.400 – galactosyltransferases MeSH D08.811.913.400.450.400.100 – n-acylsphingosine galactosyltransferase MeSH D08.811.913.400.450.400.450 – beta-n-acetylglucosaminylglycopeptide beta-1,4-galactosyltransferase MeSH D08.811.913.400.450.400.475 – ganglioside galactosyltransferase MeSH D08.811.913.400.450.400.500 – lactose synthase MeSH D08.811.913.400.450.400.500.100 – n-acetyllactosamine synthase MeSH D08.811.913.400.450.460 – glucosyltransferases MeSH D08.811.913.400.450.460.100 – 1,4-alpha-glucan branching enzyme MeSH D08.811.913.400.450.460.200 – chitin synthase MeSH D08.811.913.400.450.460.350 – glycogen debranching enzyme system MeSH D08.811.913.400.450.460.375 – glycogen synthase MeSH D08.811.913.400.450.460.400 – phosphorylases MeSH D08.811.913.400.450.460.400.186 – glycogen phosphorylase MeSH D08.811.913.400.450.460.400.186.061 – glycogen phosphorylase, brain form MeSH D08.811.913.400.450.460.400.186.124 – glycogen phosphorylase, liver form MeSH D08.811.913.400.450.460.400.186.312 – glycogen phosphorylase, muscle form MeSH D08.811.913.400.450.460.400.280 – phosphorylase a MeSH D08.811.913.400.450.460.400.327 – phosphorylase b MeSH D08.811.913.400.450.460.400.374 – starch phosphorylase MeSH D08.811.913.400.450.460.750 – starch synthase MeSH D08.811.913.400.450.480 – glucuronosyltransferase MeSH D08.811.913.400.450.560 – mannosyltransferases MeSH D08.811.913.400.450.780 – peptidoglycan glycosyltransferase MeSH D08.811.913.400.725 – pentosyltransferases MeSH D08.811.913.400.725.100 – adenine phosphoribosyltransferase MeSH D08.811.913.400.725.115 – adp ribose transferases MeSH D08.811.913.400.725.115.180 – cholera toxin MeSH D08.811.913.400.725.115.220 – diphtheria toxin MeSH D08.811.913.400.725.115.660 – nad+ nucleosidase MeSH D08.811.913.400.725.115.660.060 – adp-ribosyl cyclase MeSH D08.811.913.400.725.115.680 – pertussis toxin MeSH D08.811.913.400.725.115.690 – poly(adp-ribose) polymerases MeSH D08.811.913.400.725.115.690.840 – tankyrases MeSH D08.811.913.400.725.115.845 – sirtuins MeSH D08.811.913.400.725.130 – amidophosphoribosyltransferase MeSH D08.811.913.400.725.160 – anthranilate phosphoribosyltransferase MeSH D08.811.913.400.725.200 – ATP phosphoribosyltransferase MeSH D08.811.913.400.725.450 – hypoxanthine phosphoribosyltransferase MeSH D08.811.913.400.725.700 – orotate phosphoribosyltransferase MeSH D08.811.913.400.725.800 – purine-nucleoside phosphorylase MeSH D08.811.913.400.725.900 – thymidine phosphorylase MeSH D08.811.913.400.725.950 – uridine phosphorylase MeSH D08.811.913.400.800 – sialyltransferases
== Integrated strategy for functional assignment == The EFI is developing an integrated sequence-structure based strategy for functional assignment by predicting the substrate specificities of unknown members of mechanistically diverse enzyme superfamilies. The approach leverages conserved features within a given superfamily such as known chemistry, identity of active site functional groups, and composition of specificity-determining residues, motifs, or structures to predict function but relies on multidisciplinary expertise to streamline, refine, and test the predictions. The integrated sequence-strategy under development will be generally applicable to deciphering the ligand specificities of any functionally unknown protein.
=== Metamorphosis and cell death === Undergoing metamorphosis requires a tremendous amount of change for the fly, such as cell death. While it is commonly believed that programmed cell death and apoptosis are the same, they are not always so. At the beginning of metamorphosis during the larvae stage, salivary gland cells of Calliphora vomitoria larvae are programmed to self-destruct. After enough feeding, the larvae come to rest and an initial protein synthesis stage occurs, culminating in the production of high amounts of protein. This occurs from day 1 to about day 8. Then, on day 9, cell death of salivary gland cells occurs. This pattern of synthesis and destruction is not to be confused with apoptosis, as no DNA degeneration is seen and cells are shown to vacuolate and swell (instead of condensing and shrinking, as in the case of apoptosis). Instead, selective expression and DNA synthesis occur during programmed cell death of salivary gland cells.
Nalorphine (INNTooltip International Nonproprietary Name; also known as N-allylnormorphine; brand names Lethidrone and Nalline) is a mixed opioid agonist–antagonist with opioid antagonist and analgesic properties. It was introduced in 1954 and was used as an antidote to reverse opioid overdose and in a challenge test to determine opioid dependence. Nalorphine was the second opioid antagonist to be introduced, preceded by nalodeine (N-allylnorcodeine) in 1915 and followed by naloxone in 1960 and naltrexone in 1963. Due to potent activation of the κ-opioid receptor, nalorphine produces side effects such as dysphoria, anxiety, confusion, and hallucinations, and for this reason, is no longer used medically.
Sources: en.wikipedia.org
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.
The N-terminal modification reduces cleavage by circulating peptidases, so the peptide persists longer than native GHRH. That persistence is the main rationale for the synthetic design. Comparative half-life values in humans are reported in regulatory review documents rather than in general reference literature.
Reductions in visceral adipose tissue have been measured in controlled studies of defined populations. Whether the effect generalizes to other groups and persists after treatment stops is less clear. Longer-term outcome data remain limited.
It acts on the growth hormone–releasing hormone receptor, a Gs-coupled receptor found on pituitary somatotroph cells. Activation raises cAMP and prompts pulsatile hormone release.